Feedback
Settings

Settings

Goto Application

1. WO2021007266 - METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES

PermaLink
Publication Number WO/2021/007266
Publication Date 14.01.2021
International Application No. PCT/US2020/041095
International Filing Date 08.07.2020
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/48 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C07K 16/2809
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2809against the T-cell receptor (TcR)-CD3 complex
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
C07K 2317/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
55Fab or Fab'
Applicants
  • HEMOGENYX PHARMACEUTICALS LLC [US]/[US]
Inventors
  • SANDLER, Vladislav
Agents
  • LUBIT, Beverly W.
  • BAI, Mei
  • BOWLES, Anita, M.
  • BENNETT, Coalton
  • BLAZESKI, George
Priority Data
16/506,76409.07.2019US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES
(FR) PROCÉDÉ D'ÉLIMINATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUE/PROGÉNITEURS HÉMATOPOÏÉTIQUES (CSH/PH) CHEZ UN PATIENT À L'AIDE D'ANTICORPS BISPÉCIFIQUES
Abstract
(EN) The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
(FR) La présente invention concerne des compositions contenant des anticorps bispécifiques qui se lient à la protéine de récepteur de tyrosine kinase humaine FLT3/protéine de récepteur FLK2 et à une protéine de récepteur CD3 exprimée sur des lymphocytes T et l'utilisation des compositions contenant les anticorps bispécifiques dans la préparation d'un médicament destiné à éliminer des cellules souches hématopoïétiques/progéniteurs hématopoïétiques (CSH/PH) chez un patient.
Related patent documents
US20190389955
CA3146912
EP3997128
CN114829399
JP2022540602
Latest bibliographic data on file with the International Bureau
# -